At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 265 enrolled
Drug / intervention
AZD2281 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
In Brief
A Phase 2 clinical trial evaluating AZD2281 and matching placebo for Ovarian Cancer. Completed, enrolled 265 participants across 107 sites in 17 countries.
Detailed Summary
The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesAustralia, Austria, Belgium, Canada, Czechia, Estonia, France, Germany, Israel, Netherlands, Poland, Romania, Russia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2008
First PostedSep 2008
Primary CompletionJun 2010
Study CompletionOct 2023
TodayJul 2026
First PostedSep 16, 2008
Enrollment StartAug 28, 2008
Primary CompletionJun 30, 2010
Study CompletionOct 12, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.8 years ago
Interventions
AZD2281drug
Tablets Oral BID
matching placebodrug
matching placebo bid